Published in Hepatitis Weekly, March 29th, 2010
Hepatitis C Virus: A therapy that is a protease inhibitor that when used in combination with peg-IFN/ribavirin, achieves significantly higher SVR in genotype 1 patients with only 24 weeks of treatment compared with the standard 48 week therapy with peg-IFN/ribavirin.
Using Target Product Profiles in Your Market Strategy
Keywords: Automotive, Biotechnology, Clinical...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.